Inclusion of Biological Information in Treatment Planning Optimization Dag Rune Olsen



Similar documents
The validation of a tumour control probability (TCP) model for supporting radiotherapy treatment planning.

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Moving Beyond RECIST

Real Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer

Daily IGRT with CT-on-Rails Can Safely Reduce Planning Margin for Prostate Cancer: Implication for SBRT

DWI Case Study - QIBA PDF- MRI Technical Committee. What is IMI?

THE DOSIMETRIC EFFECTS OF

Current and Future Trends in Proton Treatment of Prostate Cancer

QUANTITATIVE IMAGING IN MULTICENTER CLINICAL TRIALS: PET

Radiation Oncology Nursing Care. Helen Lusby Radiation Oncology Nurse BAROC 2012

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward

Robert Bristow MD PhD FRCPC

Qualitative Dosimetric and Radiobiological Evaluation of High Dose Rate Interstitial brachytherapy Implants

CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA

Transition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience. Richard Pötter MD. BrachyNext, Miami, 2014.

HERC Coverage Guidance Advanced Imaging for Staging of Prostate Cancer Disposition of Public Comments

Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate

TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.

Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.

Comparison of Threshold-Based Segmentation Methods on Pre- and Post- Therapy PET Scans

Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method

Brain Tumor Treatment

Department of BioScience Technology Chung Yuan Christian University 2015/08/13

In room Magnetic Resonance Imaging guided Radiotherapy (MRIgRT( MRIgRT) Jan Lagendijk and Bas Raaymakers

Radiotherapy in locally advanced & metastatic NSC lung cancer

Immuno-Oncology Model Application in the Preclinical Treatment Setting

Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation

$ $; #! $ $ $ $. $ $, $ $,! $ # $ -$.! #,! # #. ' () «-,» ( ),. 2-3!!!, - $# (RF) #! $., - #! $ $, #. - & # $!.

Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment.

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

A new score predicting the survival of patients with spinal cord compression from myeloma

Monitoring Patient Radiation Dose in VA. Charles M. Anderson MD, PhD Chief Consultant for Diagnostic Services Veterans Health Administration

MATHEMATICAL MODELS OF TUMOR GROWTH INHIBITION IN XENOGRAFT MICE AFTER ADMINISTRATION OF ANTICANCER AGENTS GIVEN IN COMBINATION

FACULTY OF ALLIED HEALTH SCIENCES

Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies

Proton Therapy for Prostate Cancer

COMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER

Medical Applications of radiation physics. Riccardo Faccini Universita di Roma La Sapienza

P4 Distribution of Cetuximab in Models of Human Lung Cancer

Focal therapy for prostate cancer: seriously or seriously? Disclosures

Frequency of NHL Subtypes in Adults

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

Ventilation Perfusion Relationships

Medical Physics and Radioactivity

Future Directions in Cancer Research What does is mean for medical physicists and AAPM?

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

Introduction to the Monte Carlo method

Disclosures for Elena Zamagni

[Image removed due to copyright concerns]

James F. Kravec, M.D., F.A.C.P

PET. Can we afford PET-CT. Positron annihilation. PET-CT scanner. PET detection

REVIEW OF EXPOSURE LIMITS AND HEALTH CONCERNS SANTA ANA. Base Station Telecommunication Transmitters UNIFIED SCHOOL DISTRICT

Cancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi

BEYOND 18 F-FDG: INTRODUCTION TO NEW RADIOPHARMACEUTICALS

PET/CT-MRI First clinical experience

Failure Modes and Effects Analysis (FMEA)

Guidelines for pharmacokinetic and pharmacodynamic studies in early phase clinical trials

Analysis of Set-up Errors during CT-scan, Simulation, and Treatment Process in Breast Cancer Patients

Modelling the spread of brain tumours

Obtaining Knowledge. Lecture 7 Methods of Scientific Observation and Analysis in Behavioral Psychology and Neuropsychology.

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms

GAFCHROMIC DOSIMETRY MEDIA TYPE MD-V3

ASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology

Concurrent Chemotherapy and Radiotherapy for Head and Neck Cancer

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda

QA of intensity-modulated beams using dynamic MLC log files

Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology

Peptide receptor radionuclide treatment of neuroendocrine tumours

PET/CT in Breast Cancer

Prostate IMRT: Promises and Problems Chandra Burman, Ph.D. Memorial Sloan-Kettering Cancer Center, New York, NY 10021

Endpoint Selection in Phase II Oncology trials

Advanced Radiation Therapy of Cancer by Proton Beam

Estimated GFR Based on Creatinine and Cystatin C

IBA Proton Therapy. Biomed days Vincent Bossier. System Architect Protect, Enhance and Save Lives

MINIMALLY INVASIVE THERMAL THERAPY FOR CANCER TREATMENT BY USING THIN COAXIAL ANTENNAS

Dosimetry on the Intraoperative Procedure

THE ANSI/IEEE RF SAFETY STANDARD AND ITS RATIONALE. Om P. Gandhi and Gianluca Lazzi Department of Electrical Engineering Salt Lake City, Utah 84112

Cell Phone Radiation Effects on Cancer. Tyler Barkich Central Catholic High School Grade 11

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology

1. In the general symbol cleus, which of the three letters. 2. What is the mass number of an alpha particle?

Next Generation Small Animal PET Technology

MEDICAL DOSIMETRY. COLLEGE OF APPLIED SCIENCES AND ARTS Graduate Faculty: therapy.

Functional MRI for tumor delineation in prostate radiation therapy

Transcription:

Inclusion of Biological Information in Treatment Planning Optimization Dag Rune Olsen Institute for Cancer Research, Norwegian Radium Hospital, University of Oslo

Theragnostics biological conformality Tumors are often spatially and temporally heterogeneous uniform tumor dose vs non-uniform tumor dose? Treatment optimization guided by biological images of the tumor

Theragnostics biological conformality The hypothesis is that non-invasive biological imaging may provide the pertinent information to guide the painting or sculpting of the optimal dose distribution. C.C. Ling, Int. J. Radiat. Oncol. Biol. Phys. 47:551-560, 2000.

Theragnostics biological conformality Sir William Osler: The principles and practice of Medicine, 1892 If it were not for the great variability among individuals, medicine might as well be a science and not an art

Theragnostics Challenge 1: How to obtain relevant and valid biological information applicable to treatment plan optimization?

Theragnostics

Theragnostics A): Metabolism (FDG) B): proliferation (FLT) C): hypoxia (Cu-ATSM) D): angiogenesis (MMP) Apisarnthanaraxa & Chao, RADIATION RESEARCH 163, 1 25, 2005.

Theragnostics Molecular markers and tracers in PET Mechanism of FDG in functional imaging D. Heron, et al. Medical Dosimetry, 31(1):3-11, 2005.

Theragnostics Dynamic contrast enhances MRI: Perfusion, oxygenation Diffusion MRI: Cellular integrity, cell death MRSi: metabolism dce-mri

dce- MRI & tumor hypoxia Frequency (%) 35 30 25 20 15 10 5 0 po 2 (mm Hg) probe MR 0 10 20 30 40 50 60 70 80 90 100 0.20 C i ( t ) = K t Ki ( t u ) trans ν e, i i Ca( u )e 0 trans du E PERF K (ml / (g min) ) trans 0.15 0.10 0.05 0.00 0 5 10 15 20 25 30 35 40 45 po 2 (mm Hg)

dce- MRI & tumor hypoxia po 2, calc 1: > 20 mm Hg 2: 5-20 mm Hg 3: 0.5-5 mm Hg Compartmentization 4: < 0.5 mm Hg

Optimization Challenge 2: How to utilize the information in dose distribution optimization? Image of a relevant biological parameters Ideal dose map Planned dose map

Optimization Dose modifying factor: D i =OER i (p i ) * D ox

Optimization Constraint: - maintaining the mean dose to the target volume: - iso-biological effect in each voxel of the target volume: TCP = TCP [ V, ρ, α(oer),β(oer), γ ] volume density radiosensitivity repopulation rate

Optimization where f i (d) is the normalized dose distribution for compartment i, and the integration over N i (d)f i (d) yields the expected number of surviving clonogens in the given compartment. The total TCP is given by the product of the probabilities for controlling each compartment and is obtained by integrating the product over a distribution of radiation sensitivities g(α O ):

Optimization For a tumour with a non-uniform distribution of radiation sensitivity, the optimal dose distribution for a given mean dose is the distribution which gives a uniform density ρ of surviving clonogens in the tumour:

Optimization

Optimization Prescribed compartmental doses and calculated TCP for a uniform and nonuniform prescription scheme.

Optimization TCP for a non-uniform and a uniform dose distribution of equal mean dose for four cases. TCP for varying numbers of dose prescription compartments for cases 2 and 3.

Optimization

Dynamics Challenge 3: How to deal with and systematic and random errors, and spatial and temporal changes? Treatment fraction 0 3 6 9 12 15 K trans

Dynamics A B Systematic and random errors: The effect on the TCP by randomly (A) or systematically (B) assigning voxels to other tumour compartments.

Dynamics Fraction 1 Fraction 2 Fraction 3 Fraction 4 Fraction 5 Fraction 7 Fraction 9 Fraction 10 Spatial distribution of po 2 segmented into four compartments, on 16 of the 18 treatment fractions. Fraction 11 Fraction 12 2 Fraction 13 Fraction 14 4 3 1 Fraction 15 Fraction 16 Fraction 17 Fraction 18

Dynamics Hypoxic volume fractions (A) and corresponding optimal dose per treatment fraction (B) for different compartments for each of the treatment fractions.

Dynamics 40% reoxygenation TCP as a function of dose per fraction to the normoxic compartment for: no reoxygenation ( ) 10% reoxygenation ( ) 20% reoxygenation( ) 30% reoxygenation( ) 40% reoxygenation ( ) no reoxygenation The dose per fraction to the normoxic compartment was kept constant.

Dynamics uniforme dose TCP drops with increasing fraction of acute hypoxic cells, and is lowest appying a uniform dose as compared to non-uinform dose. TCP increases with increasing fraction of the chronic hypoxic celles that receive the intended dose

Dynamics

Multi-parametric optimization Challenge 4: How to deal with multiple parameters/ information?

The Pareto principle: for many events, 80% of the effects come from 20% of the causes. Does this apply to radiation oncology optimization? Can we identify the critical 20% component? Wilfried Fritz Pareto

Thank you for your attention!